Rye, NY April 23, 2013 – Curemark LLC announced a successful pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (“FDA”) regarding its CM-AT treatment for Autism.
The meeting was held to discuss Curemark’s Phase 3 trial results and the pathway for filing an NDA. In view of the positive guidance at this meeting, Curemark will yalla shoot begin filing its NDA. The FDA previously granted Curemark’s CM-AT its FAST TRACK designation.
“We continue to work closely with the FDA and appreciate its guidance as we begin filing our New Drug Application for CM-AT for autism,” commented Curemark’s CEO Dr. Joan Fallon.
Dr. Fallon continued, “The Agency’s recognition of the importance of our novel biomarker is equally exciting. We look forward to taking the next steps in bringing anagazawe.com this therapy to the children who need it.”
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about our innovative science, visit www.curemark.com.
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties gamf.net that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.